60 Degrees Pharmaceuticals Inc
SXTP
Company Profile
Business description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Contact
1025 Connecticut Avenue NW
Suite 1000
Washington, D.CWA20036
USAT: +1 202 327-5422
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.10 | 47.90 | 0.54% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,228.47 | 188.13 | 0.78% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 70,502.42 | 555.56 | 0.79% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,739.70 | 53.30 | 0.61% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |